

Compliance Alert

May 10, 2006

Compliance Alert, provided by Group Benefit Services, gives you the most up to date information regarding industry news as well as legislation and regulatory activities affecting your health plan.

TOPIC: EMERGING THERAPEUTIC ISSUE FROM ESI

Recently, Boca Medical Products issued a nationwide recall of a single lot of Ultilet Insulin Syringe 30g 1/2CC syringes. This recall is being conducted because of possible bacterial presence in the syringe, which could result in local infections following soft tissue injections. The bacteria could also contaminate the previously sterile insulin vial, resulting in degradation of the insulin which could lead to problems maintaining blood glucose control.

The recall includes the following product:

Ultilet Insulin Syringe 30g 1/2cc syringe

LOT: 5GEXI

NDC#: 08326-3002-50

The manufacturer recommends that patients who have Ultilet syringe insulin products from lot 5GEXI should stop usage and return the product to their pharmacy.

Express Scripts response:

- In an effort to inform patients of this notification, we have identified patients who may have received a prescription for Ultilet Insulin Syringe 30g 1/2cc since the lot was first distributed in September of 2005. We will send a communication to these patients, summarizing the information provided by Boca Medical Products.
- The above communication will only be distributed for those clients enrolled in the patient mailing portion of the Emerging Therapeutic Issues Program.
- Express Scripts Mail Service Pharmacies have not stocked this product.

If you have any questions regarding this information, please contact your Group Benefit Services Account Manager at 1.800.638.6085.

This communication is not intended to be legal advice and should not be construed as legal advice. If you have any legal questions or concerns about your plan, GBS recommends seeking counsel from an ERISA attorney.

Keeping you informed. Just one more reason to choose GBS.